Trial Profile
Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 21 Dec 2015 New trial record